Особенности диагностики и лечения дисфункции эндотелия у больных с первичным пролапсом митрального клапана

Аннотация

Objective: to determine the level and dynamics of the main markers of endothelial dysfunctions in pa-tients with congenital mitral valve prolapsed (MVP) with congenital mitral valve prolapsed with undifferentiat-ed connective tissue dysplasia, followed by the application and evaluation of efficacy of magnesium. We exam-ined 86 patients aged 15 to 25 (19.5±1.42) years from the primary etiological features MVP. Survey group in-cluded 41(47,7%) patients with MVP regurgitation of 1 degree and 45(52,3%) patients 2 degree. Patients in each group was administered the drug magnesium (Magnerot firm “Worwag Pharma“) at a daily dose of 3g. per day for 6 months. Patients with congenital MVP were marked signs of endothelial dysfunction (reduction of nitric oxide, increased endothelin-1) and damage it (increasing of concentration of vascular endothelial growth factor VEGF). Therapy with magnerot led to an improvement in endothelial function and prevent progression of endothelial damage